Mental Health

Compass Pathways to announce second quarter financial results on August 1, 2024

LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access…

1 year ago

Hazelden Betty Ford Reports Latest Treatment Results, Patient Outcomes

Helping People Outlive the Disease of AddictionCenter City, Minnesota--(Newsfile Corp. - July 23, 2024) - As the U.S. confronts a…

1 year ago

ViewMind Applauded by Frost & Sullivan for Revolutionizing Brain Health Assessment and Care with Its Ocular Digital Phenotyping Solution

ViewMind's Ocular Digital Phenotyping solution is a holistic approach to brain and mental health that builds trust through technology, enabling…

1 year ago

Optimi Health to Enter Asian Market with PsiloThai Collaboration on Psilocybin Research

Observational studies to focus on patients with addiction and end-of-life distress pending formal approval and permitting from Thai health authoritiesVancouver,…

1 year ago

Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer

Initial results of unprecedented trial including 10 different tumor types indicate that OnTarget did not meet its primary endpoint across…

1 year ago

BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024

BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…

1 year ago

Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression

MORRISTOWN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries…

1 year ago

Awakn Life Sciences Provides Update on Aminoindane New Chemical Entity Patent Portfolio

Toronto, Ontario--(Newsfile Corp. - July 22, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or…

1 year ago

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine’s Drug Resistance

New findings highlight potential advantages of MIRA's novel oral ketamine analog for treating neurological and neuropsychiatric disorders MIAMI, FL /…

1 year ago

Aetna Policy Update Expands TMS Availability for Adolescents With Depression

Coverage criteria consistent with recent FDA clearance for NeuroStar TMSMALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:…

1 year ago